Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-3C01 in Advanced Malignant Solid Tumors
NCT07639450Phase 2Recruiting
- Sponsor
- Hefei Xinzhu Biological Technology
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Countries
- 2
01
Overview
Phase 2, open-label trial of N-3C01 in solid tumor, sponsored by Hefei Xinzhu Biological Technology. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events up to 24 months and 7 more. Started Jun 2026; status: recruiting.
02
Drugs
N-3C01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07639450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639450.